<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00967655</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000652936</org_study_id>
    <secondary_id>LLOMGI-20050743</secondary_id>
    <secondary_id>MALIK 012009</secondary_id>
    <nct_id>NCT00967655</nct_id>
  </id_info>
  <brief_title>Capecitabine, Panitumumab, and Radiation Therapy With or Without Irinotecan Hydrochloride in Treating Patients Undergoing Surgery for Localized Rectal Cancer</brief_title>
  <official_title>A Phase II Study to Evaluate the Efficacy and Safety of Neoadjuvant Radiation in Combination With Capecitabine &amp; Paniumumab With and Without Irinotecan in Patients With Localized Rectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Loma Linda Oncology Medical Group, Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as capecitabine and irinotecan hydrochloride,&#xD;
      work in different ways to stop the growth of tumor cells, either by killing the cells or by&#xD;
      stopping them from dividing. Monoclonal antibodies, such as panitumumab, can block tumor&#xD;
      growth in different ways. Some block the ability of tumor cells to grow and spread. Others&#xD;
      find tumor cells and help kill them or carry tumor-killing substances to them. Radiation&#xD;
      therapy uses high-energy x-rays to kill tumor cells. Giving chemotherapy, monoclonal antibody&#xD;
      therapy, and radiation therapy before surgery may make the tumor smaller and reduce the&#xD;
      amount of normal tissue that needs to be removed.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying the side effects of giving capecitabine and&#xD;
      panitumumab together with radiation therapy with or without irinotecan hydrochloride and to&#xD;
      see how well it works in treating patients undergoing surgery for localized rectal cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To assess the pathological tumor response rate in patients with localized rectal cancer&#xD;
           treated with neoadjuvant chemoradiotherapy comprising capecitabine, panitumumab, and&#xD;
           radiotherapy with or without irinotecan hydrochloride.&#xD;
&#xD;
        -  To assess the incidence of grade 3/4 toxicity during neoadjuvant chemoradiotherapy.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To assess the disease-free survival.&#xD;
&#xD;
        -  To assess the time to treatment failure.&#xD;
&#xD;
        -  To assess the1-year and 2-year survival rates.&#xD;
&#xD;
        -  To assess local recurrence, defined as recurrence in pelvis at the site of previous&#xD;
           disease.&#xD;
&#xD;
        -  To assess the safety and toxicity grade using NCI CTCAE v3.0 criteria.&#xD;
&#xD;
        -  To assess the number and percentage of patients who undergo down staging of their&#xD;
           disease as determined before initiating neoadjuvant therapy and at the time of surgery.&#xD;
&#xD;
        -  To assess the number and percentage of patients where permanent colostomy can be avoided&#xD;
           as determined by the surgeon before initiating neoadjuvant therapy and at the time&#xD;
           actual surgery is performed.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
        -  Phase A: Patients undergo radiotherapy once daily 5 days a week and receive oral&#xD;
           capecitabine twice daily 5 days a week for 5½ weeks. Patients also receive panitumumab&#xD;
           IV over 1 hour on days 1, 15, and 29 during radiotherapy in the absence of disease&#xD;
           progression or unacceptable toxicity.&#xD;
&#xD;
        -  Phase B: Patients undergo radiotherapy and receive capecitabine and panitumumab as in&#xD;
           Phase A. Patients also receive irinotecan hydrochloride IV on days 1, 8, 22, and 29 in&#xD;
           the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Patients undergo surgery 6-8 weeks after completion of chemoradiotherapy,&#xD;
&#xD;
      After completion of study treatment, patients are followed up every 3 months for 1 year and&#xD;
      then every 6 months thereafter.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2009</start_date>
  <primary_completion_date type="Anticipated">July 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pathological complete response rate</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Grade 3/4 toxicity rate</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Disease-free survival</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to treatment failure</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>1-year survival rate</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>2-year survival rate</measure>
  </primary_outcome>
  <enrollment type="Anticipated">54</enrollment>
  <condition>Colorectal Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>panitumumab</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>capecitabine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>irinotecan hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>neoadjuvant therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>therapeutic conventional surgery</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed adenocarcinoma of the distal rectum (0-9 cm&#xD;
             from the dentate line or 3-12 cm from the anal verge)&#xD;
&#xD;
          -  T3 or T4 tumor or nodal involvement by endorectal ultrasound or CT scan or MRI&#xD;
&#xD;
               -  Patients with any T status where tumor is close to but not involving the&#xD;
                  sphincter who otherwise would be candidates for abdominoperineal resection are&#xD;
                  eligible&#xD;
&#xD;
          -  No known homozygotes to UGT1A1* 28&#xD;
&#xD;
          -  No distant metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status 0-1&#xD;
&#xD;
          -  ANC ≥ 1,500/mm³&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm³&#xD;
&#xD;
          -  Total bilirubin ≤ 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  ALT and AST ≤ 3 times ULN&#xD;
&#xD;
          -  Serum creatinine ≤ 1.5 times ULN&#xD;
&#xD;
          -  Creatinine clearance ≥ 50 mL/min&#xD;
&#xD;
          -  Magnesium normal&#xD;
&#xD;
          -  Able to tolerate major surgery&#xD;
&#xD;
          -  Able and willing to comply with study requirements&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 4 weeks (males) or 24&#xD;
             weeks (females) after completion of study therapy&#xD;
&#xD;
          -  No prior diagnosis of interstitial lung disease&#xD;
&#xD;
          -  No prior unanticipated severe reaction to fluoropyrimidine therapy or known&#xD;
             hypersensitivity to fluorouracil&#xD;
&#xD;
          -  No other prior or concurrent invasive malignancy unless disease-free for ≥ 5 years&#xD;
&#xD;
          -  No lack of physical integrity of the upper gastrointestinal tract, inability to&#xD;
             swallow tablets, or malabsorption syndrome&#xD;
&#xD;
          -  No concurrent serious infections&#xD;
&#xD;
          -  No clinically significant cardiovascular disease within the past year, including any&#xD;
             of the following:&#xD;
&#xD;
               -  Myocardial infarction&#xD;
&#xD;
               -  Unstable angina&#xD;
&#xD;
               -  Symptomatic congestive heart failure&#xD;
&#xD;
               -  Symptomatic coronary artery disease&#xD;
&#xD;
               -  Serious uncontrolled cardiac arrhythmia&#xD;
&#xD;
          -  No history of any medical or psychiatric condition or laboratory abnormality that, in&#xD;
             the opinion of the investigator, may increase risks associated with study&#xD;
             participation or investigational product(s) administration or may interfere with the&#xD;
             interpretation of the study results&#xD;
&#xD;
          -  No known positivity for HIV, hepatitis C, or acute or chronic active hepatitis B&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  No prior chemotherapy or radiotherapy for rectal cancer&#xD;
&#xD;
          -  No prior anti-EGFr antibody therapy (e.g., cetuximab)&#xD;
&#xD;
          -  No prior treatment with small molecule EGFr inhibitors (e.g., gefitinib, erlotinib&#xD;
             hydrochloride, or lapatinib ditosylate)&#xD;
&#xD;
          -  No prior therapeutic radiotherapy to the pelvis&#xD;
&#xD;
          -  More than 28 days since prior major surgery&#xD;
&#xD;
          -  More than 14 days since prior minor surgery&#xD;
&#xD;
          -  At least 30 days since prior investigational agent or therapy&#xD;
&#xD;
          -  At least 4 weeks since prior and no concurrent sorivudine or brivudine&#xD;
&#xD;
          -  No concurrent chronic immunosuppressive agents (e.g., methotrexate or cyclosporine)&#xD;
&#xD;
          -  No concurrent cimetidine&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Imtiaz A. Malik, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Loma Linda Oncology Medical Group, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Davood Vafai, MD, Medical Offices, Incorporated</name>
      <address>
        <city>Redlands</city>
        <state>California</state>
        <zip>92374</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pedro Bernal, MD</last_name>
      <phone>909-796-4333</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Loma Linda Oncology Medical Group, Incorporated</name>
      <address>
        <city>Redlands</city>
        <state>California</state>
        <zip>92374</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pedro Bernal, MD</last_name>
      <phone>909-796-4333</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>New Hope Cancer and Research Institute - Glendora</name>
      <address>
        <city>Redlands</city>
        <state>California</state>
        <zip>92374</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pedro Bernal, MD</last_name>
      <phone>909-796-4333</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>New Hope Cancer and Research Institute - Pomona</name>
      <address>
        <city>Redlands</city>
        <state>California</state>
        <zip>92374</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pedro Bernal, MD</last_name>
      <phone>909-796-4333</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2009</verification_date>
  <study_first_submitted>August 27, 2009</study_first_submitted>
  <study_first_submitted_qc>August 27, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 28, 2009</study_first_posted>
  <last_update_submitted>January 9, 2014</last_update_submitted>
  <last_update_submitted_qc>January 9, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 10, 2014</last_update_posted>
  <responsible_party>
    <name_title>Imtiaz A. Malik</name_title>
    <organization>Loma Linda Oncology Medical Group, Incorporated</organization>
  </responsible_party>
  <keyword>adenocarcinoma of the rectum</keyword>
  <keyword>stage I rectal cancer</keyword>
  <keyword>stage II rectal cancer</keyword>
  <keyword>stage III rectal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Panitumumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

